61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Background/Significance

The margin status after a lumpectomy is critical to determine the risk of local recurrence. Current guidelines recommend “no ink on tumor” as adequate negative margins for invasive carcinoma. Several studies report that up to 40% of patients may have positive margins requiring a second operation for excision. As such, controversy exists regarding the intraoperative management of margins, with some groups supporting routine cavity shave margins and others favoring selective margin excision based on examination of the specimen plus interpretation of intraoperative radiographs. We hypothesized that a commercially available tumor marking system used at the time of specimen radiography would help reduce the rate of margin positivity.

Materials and Methods

After Institutional Review Board approval, a retrospective review of a prospectively collected cohort of patients was conducted. We included patients older than 18 years diagnosed with invasive breast cancer undergoing breast conservation therapy. At the completion of the lumpectomy, the specimen margins were labeled using clips from the selected commercial tumor marking system; this was followed by a 2-view radiography to determine if shave margins needed to be obtained. The distance between the margin and the tumor border was recorded using a standard millimeter ruler. The radiograph was interpreted by the lead surgeon and shave margins (selective vs complete) were excised at the discretion of the lead surgeon as well. A control group with similar patient characteristics was composed using the same inclusion criteria. In this group, the commercial tumor marking system was not utilized, and the management of the margins was determined by the lead surgeon. Continuous variables are presented as mean with standard deviation and compared using t-test. Categorical variables are presented as frequencies and percentages and compared using χ2tests or Fisherexact tests, as applicable (Table). Significance level was set at 0.05. Analyses were performed using SAS software (Version 9.4).

Results

One hundred and five patients in the study group were compared with 92 patients in the control group. The mean age in both groups was 63 and 64 years, respectively. In the study group, 39% of the cohort underwent selective shave margin excision, and 7% underwent complete margin excision based on the use of the tumor marking system. The control group had a 42% rate of selective margin excision and a significantly higher rate of complete margin excision of 20%. No margins were excised in 53% of the study group vs 37% on the control group. Final pathology of the study and control groups demonstrated positive margins in 23% and 20%, respectively, with no significant difference between the groups.

Conclusion

The use of the tumor marking system did contribute to decreasing the number of patients requiring either selective or complete margin excision; however, no significant difference was found between the groups regarding the rate of margin positivity among the patients who underwent margin excision with and without the use of the tumor marking system.

Articles in this issue

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC
TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC
TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC
TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC
26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database
26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database
27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial
27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial
TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study
TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study
29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States
29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial
TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database
TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database
36 Expert Perspectives in the Management of Breast Cancer Brain Metastases: A Survey of 32 International Specialists
36 Expert Perspectives in the Management of Breast Cancer Brain Metastases: A Survey of 32 International Specialists
TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study
TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study
39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
Related Content